FinTrust Capital Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-165
| Closed | -$8K | – | 1306 |
|
|
2021
Q4 | $8K | Sell |
165
-12
| -7% | -$582 | ﹤0.01% | 956 |
|
|
2021
Q3 | $10K | Hold |
177
| – | – | ﹤0.01% | 915 |
|
|
2021
Q2 | $8K | Hold |
177
| – | – | ﹤0.01% | 969 |
|
|
2021
Q1 | $7K | Hold |
177
| – | – | ﹤0.01% | 970 |
|
|
2020
Q4 | $8K | Hold |
177
| – | – | ﹤0.01% | 896 |
|
|
2020
Q3 | $8 | Buy |
177
+140
| +378% | +$6 | ﹤0.01% | 865 |
|
|
2020
Q2 | $2K | Sell |
37
-52
| -58% | -$2.81K | ﹤0.01% | 966 |
|
|
2020
Q1 | $4K | Hold |
89
| – | – | ﹤0.01% | 925 |
|
|
2019
Q4 | $5K | Hold |
89
| – | – | ﹤0.01% | 873 |
|
|
2019
Q3 | $5K | Buy |
89
+7
| +9% | +$393 | ﹤0.01% | 872 |
|
|
2019
Q2 | $5K | Hold |
82
| – | – | ﹤0.01% | 849 |
|
|
2019
Q1 | $4K | Sell |
82
-369
| -82% | -$18K | ﹤0.01% | 997 |
|
|
2018
Q4 | $18K | Buy |
+451
| New | +$18K | 0.01% | 621 |
|